• Users Online: 8
  • Home
  • Print this page
  • Email this page


 
 Table of Contents  
ARTICLE
Year : 2014  |  Volume : 3  |  Issue : 2  |  Page : 132-138

Active tuberculosis case finding and detection of drug resistance among HIV-infected patients: A cross-sectional study in a TB endemic area, Gondar, Northwest Ethiopia


1 Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, P.O. Box: 196, Gondar; Armauer Hansen Research Institute, P.O. Box: 1005, Addis Ababa, Ethiopia
2 Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, University of Gondar, P.O. Box: 196, Gondar, Ethiopia
3 Armauer Hansen Research Institute, P.O. Box: 1005, Addis Ababa, Ethiopia
4 School of Medicine, Division of Infectious Diseases, Emory University, Atlanta, GA 30303, USA

Date of Web Publication26-Feb-2017

Correspondence Address:
Martha Alemayehu
Department of Medical Microbiology, University of Gondar, P.O. Box: 196, Gondar
Ethiopia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.ijmyco.2014.02.004

Get Permissions

  Abstract 


Background: Tuberculosis (TB) patients co-infected with human immunodeficiency virus (HIV) often lack the classic symptoms of pulmonary tuberculosis, making the diagnosis difficult. Current practices in resource-limited settings often indicate that these co-infected patients are diagnosed when they clinically manifest disease symptoms, resulting in a delayed diagnosis and despite continued transmission. The aim of this study is to determine the prevalence of undiagnosed pulmonary tuberculosis cases through active case finding and including multidrug-resistant TB (MDR-TB) among HIV-infected patients.
Materials and methods: A total of 250 HIV-infected patients, aged 18 years and above were evaluated in a cross-sectional design between February 2012 and November 2012. Socio-demographic and clinical data were collected using a structured questionnaire. Sputum samples were collected from all participants for acid fast bacilli (AFB) direct smear microscopy and Mycobacteria culture. A PCR-based RD9 deletion and genus typing, as well as first-line anti-TB drug susceptibility testing, was performed for all culture-positive isolates.
Results: Following active TB case finding, a total of 15/250 (6%) cases were diagnosed as TB cases, of whom 9/250 (3.6%) were detected by both smear microscopy and culture and the remaining 6/250 (2.4%) only by culture. All the 15 isolates were typed through RD9 typing of which 10 were Mycobacterium tuberculosis species; 1 belonged to Mycobacterium genus and 4 isolates were non-tuberculous mycobacteria. The prevalence of undiagnosed pulmonary TB disease among the study participants was 4.4%, which implies the possibility of identifying even more undiagnosed cases through active case finding. A multivariate logistic regression showed a statistically significant association between the presence of pneumonia infection and the occurrence of TB (OR = 4.81, 95% CI (1.08–21.43), p = 0.04). In addition, all the isolates were sensitive to all first-line anti-TB drugs, except for streptomycin, seen in only one newly diagnosed TB patient, and MDR-TB was not detected.
Conclusion: The prevalence of undiagnosed pulmonary TB infection among HIV-infected patients in Gondar was 4.4%. Additionally, the possibility of these undiagnosed TB cases in the community could also pose a risk for the transmission of the disease, particularly among family members. Active screening of known HIV-infected individuals, with at least one TB symptom is recommended, even in persons with opportunistic infections.

Keywords: Active case finding, HIV, TB, Drug resistance, Northwest Ethiopia


How to cite this article:
Alemayehu M, Gelaw B, Abate E, Wassie L, Belyhun Y, Bekele S, Kempker RR, Blumberg HM, Aseffa A. Active tuberculosis case finding and detection of drug resistance among HIV-infected patients: A cross-sectional study in a TB endemic area, Gondar, Northwest Ethiopia. Int J Mycobacteriol 2014;3:132-8

How to cite this URL:
Alemayehu M, Gelaw B, Abate E, Wassie L, Belyhun Y, Bekele S, Kempker RR, Blumberg HM, Aseffa A. Active tuberculosis case finding and detection of drug resistance among HIV-infected patients: A cross-sectional study in a TB endemic area, Gondar, Northwest Ethiopia. Int J Mycobacteriol [serial online] 2014 [cited 2017 Oct 23];3:132-8. Available from: http://www.ijmyco.org/text.asp?2014/3/2/132/200943




  Introduction Top


Tuberculosis (TB) is one of the leading opportunistic infections that affect people living with human immunodeficiency virus (HIV) leading to significant morbidity and mortality [1]. People living with HIV are about 21–34 times more likely to develop TB disease compared with those who are HIV-negative [2]. TB in such patients is often difficult to diagnose because of nonspecific symptoms, atypical or normal chest radiograph findings, negative results of sputum smear microscopy and lack of culture facilities in resource-limited settings [3].

Active TB screening can prompt earlier treatment initiation, reducing the burden of disease in an individual and transmission within the community [4],[5]. In 2004, the World Health Organization (WHO) has recommended routine screening for active TB disease in all patients living with HIV, with treatment provided for active TB disease or isoniazid preventive therapy (IPT) for latent TB to reduce morbidity and mortality [6]. However, since this recommendation, only 2.3 million individuals have been screened for TB, of whom 178,000 were offered IPT [2]. Africa accounted for 82% of new TB cases among people living with HIV [2]. According to the 2011 WHO tuberculosis report, Ethiopia ranked seventh among the world's 22 high-burden countries with an estimated incidence of 333 per 100,000 populations per year [2],[7].

In addition, the emergence of multidrug resistance (MDR) is also one of the threatening factors for many TB control programs globally [8]. Drug-resistant TB is expected to exist in countries like Ethiopia where there is high risk of infection with HIV, as drug resistance has been significantly associated with HIV infection [9]. According to the WHO estimate, the prevalence of MDR-TB in Ethiopia has been estimated to be 1.6% among newly diagnosed cases and 12% among retreatment cases [2]. MDR-TB has progressed to extensively-drug resistant status (XDR-TB) [10] and the latter have evolved in some parts of the world to totally-drug resistant (TDR-TB) infections [11]. The presence of XDR-TB has not been thoroughly investigated in Ethiopia. Recently, two XDR-TB strains were reported from a total of 45 MDR-TB cases in a study conducted at St. Peter's TB Specialized Hospital and Ethiopian Health and Nutrition Research Institute [12]. TDR-TB-a yet-to-be-defined infection – is believed to be resistant to all forms of therapy, and mortality is almost certain [11].

Although many factors such as the degree of immunosuppression, high-risk behavior, lifestyle and TB contact history contribute to the development of active TB in HIV-positive patients [13],[14],[15], delays in early diagnosis of TB can also play an important role in morbidity and mortality among HIV patients. To the knowledge of this study, this is the first report done among HIV-infected patients to assess the prevalence of undiagnosed pulmonary TB, anti-TB drug susceptibility patterns and associated risk factors, who attend anti-retroviral (ARV) clinics in the Gondar area, Ethiopia, through active case findings.


  Materials and methods Top


Study design and participants

A cross-sectional study was conducted between February 2012 and November 2012 among HIV patients attending the ARV clinic at the Gondar University Hospital, a tertiary-level teaching and referral hospital in Northwest Ethiopia. A total of 250 consecutive HIV patients, aged 18 years and above and who at least had one of the TB symptoms (cough, night sweats, fever or weight loss), but undiagnosed during their visit at the clinic were enrolled.

In addition, patients with a history of previous TB and those on anti-retroviral treatment (ART) or pre-ART were also enrolled. Those patients with severe illness and unable to provide sputum and who already started anti-TB treatment or IPT were excluded. Socio-demographic features ([Table 1]) and clinical data ([Table 2]), including chest X-ray findings, were collected using structured questionnaires.
Table 1: Socio-demographic characteristics of the study participants (n = 250) from antiretroviral Clinic at Gondar University Hospital, Northwest Ethiopia, 2012.

Click here to view
Table 2: Baseline clinical data of the study participants (n = 250) from antiretroviral Clinic at Gondar University Hospital, Northwest Ethiopia, 2012.

Click here to view


The clinical presentation of HIV positive cases were non-specific, such as an acute mononucleosis-like illness accompanied by fevers, sweats, malaise, lethargy, anorexia, nausea, myalgia, arthralgia, headache, sore throat, diarrhea, lymphadenopathy and rash [16].

Sputum collection and processing

Three sputum samples (spot-morning-spot samples) were collected from all eligible participants, pooled and a direct acid fast bacilli (AFB) smear microscopy was performed using the conventional Ziehl–Neelsen staining technique at the Gondar Microbiology Laboratory as described earlier [17]. The remaining aliquots of sputa were transported in a cold chain from Gondar Microbiology Laboratory to the P3 TB laboratory facility at Armauer Hansen Research Institute (AHRI), Addis Ababa, for Mycobacterium culture, RD typing and drug susceptibility testing.

Mycobacterial culture

Sputum samples were decontaminated and homogenized by the modified Petroff's method as described previously [18]. Briefly, about 1 ml of the sediment was inoculated into the conventional Lowenstein-Jensen (LJ) egg slant medium containing 0.6% sodium pyruvate and glycerol for primary isolation. After inoculation, LJ slants were held for 8weeks at 37 °C and visually inspected for growth every day for the first week and twice per week thereafter for the total of 8weeks for the presence of mycobacterial colonies. Microscopic examinations of the colonies were performed using Ziehl–Neelsen staining method so as to select AFB positive isolates.

Molecular typing

Heat-killed cells were prepared from AFB positive isolates by mixing two loops-full of colonies in 200 μl of distilled water and by heating at 80oC for one hour. Polymerase Chain Reaction (PCR)-based deletion typing was performed to check for the presence or absence of regions of difference-9 (RD9) so as to identify Mycobacterium tuberculosis (M. tuberculosis) from other species of Mycobacteria [19]. The method was applied to heat-killed mycobacterial suspensions. A multiplex PCR was designed to amplify the non-deleted RD9 region. Two external primers (RD9_FlankFW: 5’ -AACACGGTCACGTTGTCGTG-3’ and RD9_FlankRev: 5’ -CAAACCAGCAGCTGTCGTTG-3’ ) and one internal reverse primer (RD9_InternalR: 5’ -TTGCTTCCCCGGTTCGTCTG-3’ ) were used per locus.

After identification by RD9 typing, Mycobacterium genus typing was performed from non-deleted RD9 region to further differentiate species of the M. tuberculosis complex from other Mycobacterium species. A reference strain of M. tuberculosis, H37Rv (ATCC 27249) and water were also run simultaneously with samples in every reaction as positive and negative controls, respectively.

Drug susceptibility testing (DST)

Indirect drug susceptibility testing was performed for first-line anti-TB drugs (isoniazid, rifampicin, ethambutol and streptomycin), based on proportion method on 24-well tissue culture plates (Becton Dickinson, USA) using Middlebrook 7H10 medium supplemented with glycerol and 10% oleic acid albumin dextrose catalase (OADC; Becton Dickinson, Sparks, MD). Primary isolates grown within 2–3weeks were used for preparing the suspension, then the DST plates were inoculated by adding 10 μl of the suspension which was adjusted with McFarland standard. The plates were securely sealed with Parafilm and incubated at 35 °C in a 5% CO2 incubator with a water reservoir. Drug susceptibility was determined by visually comparing the drug containing media (1:1 bacterial suspensions) with the drug-free control on which 1:100 bacterial suspensions was inoculated. The drug sensitivity of the bacterial isolate was later determined using the critical concentration level as recommended by the WHO 2009 [20].

Statistical analysis

Data analysis was performed using SPSS software packages Version 20.0 (SPSS Inc., Chicago, 2011, USA). Descriptive statistics was used to report patient socio-demographics and clinical data, prevalence of undiagnosed pulmonary TB and rates of MDR-TB. Logistic regression and odds ratio were used to measure the degree of association between the different variables. A p-value of < 0.05 was considered statistically significant.

Ethical consideration

The study received ethical approval from the ethics board of the University of Gondar, School of Biomedical and Laboratory Sciences, and AHRI/ALERT Ethics Review Committee and all participants gave written informed consent.


  Results Top


Of the 250 participants who were actively screened for TB, 15 (6%) cases were identified as having TB, of whom 9 were newly detected TB cases and positive by both smear microscopy and culture, and the remaining were previously treated TB cases (patients who had a previous history of TB and completed TB treatment at least 3 months previously and not identified as TB suspect during the study period) and detected only using culture. RD9 typing also showed that ten of the isolates were M. tuberculosis species, one belonged to Mycobacterium genus, which could not be specified due to inaccessibility of the test kits and the remaining four isolates were non-tuberculous mycobacteria, further indicating the prevalence of undiagnosed pulmonary TB disease in the study cohort to be 4.4% (11/250).

The overall CD4 T-cell count was relatively higher among non-TB cases compared with TB cases ([Table 3]), although there was no statistically significant association. Logistic regression analyses showed no significant association between different variables and risk factors for pulmonary TB disease, except for the presence of pneumonia (OR = 4.81, 95% CI [1.08–21.43], p = 0.04) ([Table 4]).
Table 3: Immunological status of the study participants (n = 250), as depicted by CD+4 T-cell count, Gondar University Hospital, Northwest Ethiopia, 2012.

Click here to view
Table 4: Analyses of risk factors for pulmonary TB among study participants (n = 250), Gondar University Hospital, Northwest Ethiopia, 2012.

Click here to view


On the other hand, analyses of drug susceptibility testing showed that all of the 11 Mycobacterium isolates became sensitive to all first-line anti-TB drugs, except for one isolate, which was obtained from a newly diagnosed TB case that was resistant to streptomycin. No MDR-TB was detected in the study cohort in both newly diagnosed cases and previously treated TB cases.


  Discussion Top


The current study identified about 4.4% of undiagnosed pulmonary TB among a cohort of HIV-infected individuals visiting ART clinics in the Gondar area, where the majority were also smear positive/culture positive (3.6%) implying the possibility of identifying even more undiagnosed cases through active case finding. In addition, the possibility of these undiagnosed TB cases in the community could also pose a risk for the transmission of the disease, particularly among family members. This observation is relatively higher than what has been reported from South Africa among HIV-positive gold miners, where the point prevalence of undiagnosed TB and the rate of smear-positive TB were 3.8% and 0.4%, respectively [21]. This difference could also be attributed to the use of IPT among the South African gold miners that could reduce the occurrence of symptomatic disease due to TB.

A case-control study conducted in Northwest Ethiopia by Animut et al. showed that out of 282 TB patients, 54.6%, 23.8% and 21.6% had smear negative, smear positive and extra pulmonary TB, respectively, and identified several predictors of HIV counseling and testing among TB patients which is in contrast to this study [22]. The difference is in this study all participants were known HIV patients screened for TB but not TB patients.

On the other hand, a study conducted in one of the research clinics in Gambia reported a significantly higher proportion of TB (43.2%) among HIV patients, of whom 66% had pulmonary TB confirmed by microscopy and/or culture [23]. In a similar trend, a higher prevalence of pulmonary TB was reported among HIV-positive patients in Cambodia [24]. Part of these differences in the two reports was mainly due to differences in inclusion and exclusion criteria, where in this case all patients who were already diagnosed with TB and started anti-TB treatments were excluded.

The finding from the RD9 typing also demonstrates that the dominant causative agent for TB in the study population was M. tuberculosis, as more than 60% of the isolates were confirmed to be M. tuberculosis. This has been also evident from earlier studies conducted in other regions of Ethiopia [25],[26]. This study also evaluated the association of TB occurrence with different risk factors, such as age, sex, residence area, occupation, education, marital status, alcohol intake, tobacco or shisha use, previous TB contact history, stages of HIV or ART use and CD4 count; however, none of these factors significantly correlated with the occurrence of TB (p>0.05). Similar observations were also reported earlier [27].

All the mycobacterial isolates tested in this study showed no resistance to all first-line anti-TB drugs, except for one isolate which was resistant to streptomycin. This is in contrast to previous MDR-TB reports conducted in the country, which is about 1.6% among new cases and 12% in re-treatment cases [9],[28] and elsewhere [29],[30],[31],[32]. It should be noted from the current study that only a few HIV positive cases that had at least one TB symptom but were undiagnosed at the attending clinic (newly diagnosed) or those who completed TB treatment at least 3 months prior to the study (previously treated cases, but not retreatment cases) were considered, and hence a few TB-positive cases were identified, which may underestimate the overall prevalence of drug resistance among the HIV-infected population. On the other hand, a study from Cambodia showed a decreasing trend of anti-TB drug resistance (48% in 1999 to 7.9% in 2004) since the introduction of ART drugs [33]. These observations may possibly imply the fact that the introduction of ART may play a role in limiting the emergence of anti-TB drug resistance. Despite this, the observed prevalence in the current study could not be overlooked, as these identified cases could still be major sources of infection and transmission in the community.

In addition, TB is the most common opportunistic infection and is the leading cause of mortality in HIV-infected persons. TB disease has been shown to accelerate the natural course of HIV disease, and, similarly, HIV infection results in a more rapid progression from latent TB infection to TB disease. However, diagnosing TB in HIV-infected persons is a major public health challenge.

In general, considering the observed prevalence of undiagnosed TB among HIV-positive patients, health professionals, particularly those working in ART facilities, should critically evaluate HIV patients clinically regardless of their ART use and actively screen for TB at least through microscopic examination of TB to detect cases early and initiate anti-TB or isoniazid preventive treatments. Further community-based surveys are warranted to confirm the current findings.


  Conflict of interest Top


The authors declare that they have no competing interests.


  Acknowledgements Top


This study was funded by the University of Gondar and Armauer Hansen Research Institute. We greatly thank Mr. Abiyot Abeje, head nurse of ART clinic, and Mrs. Kidest Alemayehu, laboratory technician from Gondar University Hospital, who greatly contributed to the recruitment of study participants. Our special gratitude also goes to the study participants for taking part in the study.



 
  References Top

1.
C. Dye, Global epidemiology of tuberculosis, Lancet 367 (2006) 938–940.  Back to cited text no. 1
    
2.
World Health Organization, Global Tuberculosis control report: WHO, WHO, Geneva, 2011.  Back to cited text no. 2
    
3.
S.D. Lawn, D.J. Edwards, K. Kranzer, M. Vogt, L.G. Bekker, R. Wood, Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease, AIDS 23 (2009) 1875–1880.  Back to cited text no. 3
    
4.
S. Shah, M. Demissie, L. Lambert, J. Ahmed, S. Leulseged, T. Kebede, et al, Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia, Epidemiol. Soc. Sci. 50 (5) (2009) 537–545.  Back to cited text no. 4
    
5.
M. Abebe, M. Doherty, L. Wassie, A. Demissie, A. Mihret, H. Engers, et al, TB case detection: can we remain passive while the process is active?, Pan Afr. Med. J. 11 (2012) 50.  Back to cited text no. 5
    
6.
World Health Organization, Interim policy on collaborative TB/HIV activities, WHO, Geneva, 2004.  Back to cited text no. 6
    
7.
Federal Ministry of Health. Annual Health Service Report. Addis Ababa, Ethiopia, 2010.  Back to cited text no. 7
    
8.
WHO/IUATLD. Anti-Tuberculosis Drug Resistance in the World: the WHO/IUATLD Global Project on Anti-tuberculosis Dug Resistance Surveillance. Report 2: Prevalence and Trends. World Health Organization, Geneva, WHO/CDS/TB/ 2000, p. 278.  Back to cited text no. 8
    
9.
G. Mitike, D. Kebede, H. Yeneneh, HIV infection and antituberculosis drug resistance among pulmonary tuberculosis patients in Harar tuberculosis centre Ethiopia, East Afr. Med. J. 74 (1997) 154–157.  Back to cited text no. 9
    
10.
Centers for Disease Control and Prevention, [CDC]. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm. Rep. 58(RR-3) (2009) 1–43.  Back to cited text no. 10
    
11.
Z.F. Udwadia, R.A. Amale, K.K. Ajbani, C. Rodrigues, Totally drug-resistant tuberculosis in India, Clin. Infect. Dis. 54 (4) (2012) 579–581.  Back to cited text no. 11
    
12.
M. Agonafir, E. Lemma, D. Wolde-Meskel, S. Goshu, A. Santhanam, F. Girmachew, et al, Phenotypic and genotypic analysis of multidrug-resistant tuberculosis in Ethiopia, Int. J. Tuberc. Lung Dis. 14 (2010) 1259–1265.  Back to cited text no. 12
    
13.
M.M.S. Boffo, I.G. Mattos, M.O. Ribeiro, I.C.O. Netto, Tuberculosis associated with AIDS: demographic, clinical and laboratory findings in patients from a referral center in southern Brazil, J. Pneumol. 30 (2) (2004) 140–146.  Back to cited text no. 13
    
14.
A.R. Moss, J.A. Hahn, J.P. Tulsky, C.L. Daley, P.M. Small, P.C. Hopewell, Tuberculosis in the homeless. A prospective study, Am. J. Respir. Crit. Care Med. 162 (2 Pt. 1) (2000) 460–464.  Back to cited text no. 14
    
15.
P. Godoy, A. Domínguez, J. Alcaide, N. Camps, J.M. Jansa`, S. Minguell, et al, Working Group of the Multicentre Tuberculosis Research Project. Characteristics of tuberculosis patients with positive sputum smear in Catalonia, Spain, Eur. J. Public Health 14 (1) (2004) 71–75.  Back to cited text no. 15
    
16.
D.A. Cooper, J. Gold, P. Maclean, B. Donovan, R. Finlayson, T.G. Barnes, et al, Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion, Lancet 1 (1985) 537–540.  Back to cited text no. 16
    
17.
B. Anagaw, A. Mulu, E. Abate, B. Anagaw, T. Belay, A. Gelaw, et al, Improved detection of acid-fast bacilli in sputum by the bleach-concentration technique at Gondar University Teaching Hospital northwest Ethiopia, Ethiop. Med. J. 50 (4) (2012) 349–354.  Back to cited text no. 17
    
18.
I. Narvaiz, K. Kim, T. Frieden, A. Laszlo, F. Luelmo, P. Norval, et al, Laboratory Services in Tuberculosis Control, WHO, Geneva, Switzerland, 1998.  Back to cited text no. 18
    
19.
R. Warren, N. Gey van Pittius, M. Barnard, A. Hesseling, E. Engelke, M. De Kock, et al, Differentiation of Mycobacterium tuberculosis complex by PCR amplification of genomic regions of difference, Int. J. Tuberc. Lung Dis. 10 (2006) 818–822.  Back to cited text no. 19
    
20.
World Health Organization. Guidelines for Surveillance of drug Resistance in Tuberculosis. WHO Report, 4th ed., Geneva, WHO, 2009.  Back to cited text no. 20
    
21.
E.L. Corbett, S. Charalambous, V.M. Moloi, K. Fielding, A. Grant, C. Dye, et al, Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners, Am. J. Respir. Crit. Care Med. 170 (2004) 673–679.  Back to cited text no. 21
    
22.
A. Animut, L. Abenet, C. Robert, D. Amare, Predictors of HIV testing among patients with tuberculosis in North West Ethiopia: a Case-Control Study, PLoS One 5 (3) (2010) e9702.  Back to cited text no. 22
    
23.
M.H. Haileyeus Getahun, R. O'Brien, P. Nunn, Diagnosis of Smear negative pulmonary tuberculosis in a people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes, Lancet Public Health 369 (9578) (2007) 2042–2049.  Back to cited text no. 23
    
24.
M.A. van der Sande, van der Schim, M.F. van der Loeff, R.C. Bennett, M. Dowling, A.A. Aveika, et al, Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2, AIDS 18 (2004) 1933–1941.  Back to cited text no. 24
    
25.
J. Bruchfeld, G. Aderaye, I.P. Berggren, B. Bjorvatn, S. Ghebremichael, S. Hoffner, et al, Molecular epidemiology and drug resistance of Mycobacterium tuberculosis isolates from Ethiopian pulmonary tuberculosis patients with and without human immunodeficiency virus infection, J. Clin. Microbiol. 40 (5) (2002) 1636–1643.  Back to cited text no. 25
    
26.
D. Beyene, I. Bergva, E. Hailu, S. Ashenafi, L. Yamuah, A. Aseffa, et al, Identification and genotyping of the etiological agent of Tuberculous lymphadenitis in Ethiopia, J. Infect. Dev. Ctries. 3 (6) (2009) 412–419.  Back to cited text no. 26
    
27.
R. Iwnetu, J. Van Den Hombergh, Y.Woldeamanuel, M. Asfaw, C. Gebrekirstos, Y. Negussie, et al, Is Tuberculous lymphadenitis over-diagnosed in ethiopia? comparative performance of diagnostic tests for Mycobacterial lymphadenitis in a highburden country, Scand. J. Infect. Dis. 41 (2009) 462–468.  Back to cited text no. 27
    
28.
G. Abate, Review: drug resistance tuberculosis in Ethiopia problem scenarios and recommendation, Ethiop. Med. J. 40 (2002) 79–86.  Back to cited text no. 28
    
29.
G.S. Kibiki, B. Mulder, W.M. Dolmans, J.L. de Beer, M. Boeree, N. Sam, et al, M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania, BMC Microbiol. 7 (2007) 51.  Back to cited text no. 29
    
30.
J. van den Broek, S. Mfinanga, C. Moshiro, R. O'Brien, A. Mugomela, M. Lefi, Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania, Int. J. Tuberc. Lung Dis. 2 (1998) 547–552.  Back to cited text no. 30
    
31.
M. Zignol, M.S. Hosseini, A. Wright, C.L. Weezenbeek, P. Nunn, C.J. Watt, B.G. Williams, et al, Global incidence of multidrug-resistant tuberculosis, J. Infect. Dis. 194 (2006) 479– 485.  Back to cited text no. 31
    
32.
A. van Deun, K.J. Aung, S. Chowdhury, S. Saba, A. Pankaj, A. Ashraf, et al, Drug susceptibility of Mycobacterium tuberculosis in a rural area of Bangladesh and its relevance to the national treatment regimens, Int. J. Tuberc. Lung Dis. 3 (1999) 143–148.  Back to cited text no. 32
    
33.
S. Sungkanuparph, B. Eampokalap, S. Chottanapund, S.T. Bed, W. Manosuthi, Declining prevalence of drug-resistant tuberculosis among HIV/tuberculosis co-infected patients receiving antiretroviral therapy, J. Med. Assoc. Thai. 90 (2007) 884–888.  Back to cited text no. 33
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]


This article has been cited by
1 Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis
Setegn Eshetie,Mucheye Gizachew,Mulat Dagnew,Gemechu Kumera,Haile Woldie,Fekadu Ambaw,Belay Tessema,Feleke Moges
BMC Infectious Diseases. 2017; 17(1)
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Materials and me...
Results
Discussion
Conflict of interest
Acknowledgements
References
Article Tables

 Article Access Statistics
    Viewed42    
    Printed0    
    Emailed0    
    PDF Downloaded14    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]